Patent Reform Face-Off Turns To Face Time For Pharma And Tech Companies
Executive Summary
Pushing to craft a final patent reform bill that's acceptable to everyone, Senator Patrick Leahy. D-Vt., called together representatives from the pharmaceutical, biotech, software and financial services industries, universities, labor organizations and inventors. The groups hunkered down with Leahy's staff on Sept. 24 to tweak the bill's provisions
You may also be interested in...
Will Pharma Weather The Economic Storm? Doomsday Predictions Often Wrong
BOSTON - The current economic downturn is part of a cyclical trend, and if the past is any indicator, the pharmaceutical industry will weather the storm and emerge on top, NicOx VP-Commercial Affairs Sanjiv Sharma contends
Will Pharma Weather The Economic Storm? Doomsday Predictions Often Wrong
BOSTON - The current economic downturn is part of a cyclical trend, and if the past is any indicator, the pharmaceutical industry will weather the storm and emerge on top, NicOx VP-Commercial Affairs Sanjiv Sharma contends
Patent Reform Bill Clears House; BIO Opposes Provision on Damages Awards
A House patent reform provision on apportionment of damages in infringement suits is likely to be revised, despite House passage of the legislation Sept. 7 by a vote of 220-175